Medical Science Liaison

Larimar Therapeutics Inc. (Larimar) is a publicly held clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Our lead product candidate, Nomlabofusp (formerly referred to as CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia (FA).

Friedreich’s ataxia is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.

Larimar Therapeutics Inc. (Larimar) is a publicly held clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Our lead product candidate, Nomlabofusp (formerly referred to as CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia (FA).

Friedreich’s ataxia is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.

The company has assembled an experienced management team, each of whom has over 20 years of pharmaceutical industry experience and has over 50 employees. Their management team, employees, and consultants have significant expertise in discovery, nonclinical and clinical development, regulatory affairs, and the development of manufacturing processes utilizing good manufacturing practices.

The company’s strategy is to become a leader in the treatment of rare diseases by leveraging their technology platform and applying their team’s know-how to the development of nomlabofusp and other future pipeline projects. We are best characterized by entrepreneurial and scientific leadership and a participatory workforce committed to success.

This position is field based with approximately 50-60% travel.

The Medical Science Liaison (MSL) is part of the field-based medical affairs teams that plays an important role establishing, cultivating, and maintaining relationships with strategic external stakeholders, specifically key opinion leaders (KOLs) and healthcare professionals (HCPs) in relevant therapeutic areas. The primary responsibilities of the Larimar MSLs will be to provide high quality two-way medical and scientific communication, delivering nonclinical, medical, and pharmacoeconomic information that is consistent and aligns with published and proprietary knowledge of therapeutic areas of interest and Larimar products that are marketed or under development.

MSLs will be expected to leverage his or her medical and scientific background, industry knowledge, and business acumen to engage in appropriate, fair and balanced communication with KOLs and HCPs. In addition, MSLs will also provide support for research initiatives, medical education, presentations and publications, congresses, meetings, advisory boards, and other Medical Affairs activities. MSLs may also, from time to time, serve as a subject matter expert for internal stakeholders if appropriate.

While MSLs will be expected to operate independently in the field, the execution of day-to-day duties will be an extension of the MSL team, the Medical Affairs function, and the Larimar organization. Larimar MSLs must fit well within Larimar’s culture of excellence, collaboration, and respect, and conduct themselves professionally in a manner that is compliant with law, regulation, and Larimar’s internal policies.